I-Mab (NASDAQ:NBP) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of I-Mab (NASDAQ:NBP) from a hold rating to a sell rating in a research note published on Sunday morning,Wall Street Zen reports.

Several other brokerages also recently weighed in on NBP. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of I-Mab in a research report on Thursday, August 20th. Weiss Ratings upgraded I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

I-Mab Trading Down 4.9%

Shares of NBP stock opened at $1.73 on Friday. The company has a market cap of $200.07 million, a PE ratio of -4.81 and a beta of 1.50. The company’s fifty day simple moving average is $1.83 and its 200-day simple moving average is $2.21. I-Mab has a 52 week low of $1.46 and a 52 week high of $6.79.

I-Mab (NASDAQ:NBP) last announced its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share (EPS) for the quarter. Equities research analysts expect that I-Mab will post -0.3 EPS for the current fiscal year.

Institutional Trading of I-Mab

An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group acquired a new stake in I-Mab (NASDAQ:NBP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is currently owned by institutional investors.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.